Therapeutic effect of umbilical cord blood cells on spinal cord injury

Abstract

Spinal cord injury (SCI) is a nervous system disease characterized by sensory and motor dysfunction, axonal apoptosis, decreased vascular density, and inflammation. At present, surgical treatment, drug treatment, and cell therapy can be used. Surgical treatment can improve motor and independent function scores, and drug treatment can promote the recovery of neurons in the spinal cord, but only improve symptoms. Complete recovery of SCI has not yet been achieved. However, the differentiation of stem cells brings hope for the treatment of SCI. Umbilical cord blood cells (UCBs) are ethically readily available and can repair neuronal damage. However, it is still unclear how they can improve symptoms and repair nerve severity. In this paper, the role of UCBs in the treatment of SCI is described in detail from different aspects such as behavior, morphology, and molecular expression changes, so as to provide new ideas and theoretical directions for future research.

Epigenetic regulation and factors that influence the effect of iPSCs-derived neural stem/progenitor cells (NS/PCs) in the treatment of spinal cord injury

“…However, these cells also exhibit limited capacity for differentiation and integration [ 12 , 13 ]. Schwann cells (SCs), olfactory ensheathing cells (OECs), NSCs, and umbilical cord blood derived cells (UCBDCs) are other cell types that have been tested for SCI therapy, with varying degrees of success and limitations [ 14 – 16 ]. In addition, hair follicle stem cells (HFSCs) and epidermal neural crest stem cells (EPI-NCSCs) are currently being investigated as potential cell-based therapies for SCI [ 17 , 18 ] (Table 1 ).…”